Ivermectin for the control of scabies outbreaks in the UK

Article (Accepted Version)


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/85729/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Accepted manuscript (distributed under CC-BY-NC-ND):

**Endorsed by WHO as effective and safe, it is time to make ivermectin available to control scabies outbreaks in the UK**

Jo Middleton¹,², Stephen L. Walker³,⁴, Thomas House⁵,⁶, Michael G. Head⁷, Prof Jackie A. Cassell¹,⁸

¹Department of Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK ²Evolution, Behaviour and Environment, School of Life Sciences, University of Sussex, Falmer, UK ³Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK ⁴Hospital for Tropical Diseases and Department of Dermatology, University College London Hospitals NHS Foundation Trust, London, UK ⁵School of Mathematics, University of Manchester, Manchester, UK ⁶IBM Research, Hartree Centre, Sci-Tech Daresbury, UK ⁷Faculty of Medicine and Global Health Research Institute, University of Southampton, Southampton, UK ⁸Surrey and Sussex Health Protection Team, Public Health England, Horsham, UK.

**Corresponding author**

Jo Middleton, Department of Primary Care and Public Health, Brighton and Sussex Medical School, Room 319, Watson Building, Falmer, BN1 9PH

Email: j.middleton@bsms.ac.uk  https://orcid.org/0000-0001-5951-6608

**Full addresses of all other authors**

Stephen L. Walker, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK

Thomas House, School of Mathematics, University of Manchester, Oxford Road, Manchester, M13 9PL, UK

Michael G. Head, Clinical Informatics Research Unit, Global Health Research Institute, University of Southampton, Coxford Road, Southampton, SO16 5AF, UK

Professor Jackie A. Cassell, Department of Primary Care and Public Health, Brighton and Sussex Medical School, Room 318a, Watson Building, Falmer, BN1 9PH, UK
On July 9th 2019, WHO updated it’s ‘Model List of Essential Medicines’ to include oral ivermectin for ectoparasitic infections.\(^1\) This recommendation follows the 2017 WHO categorization of scabies as a Neglected Tropical Disease. The list covers the ‘minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost–effective medicines for priority conditions’.\(^1\) In the UK scabies outbreaks remain a significant public health burden in care homes for elderly people.\(^2\) Yet this essential, and safe, medicine remains unlicenced for scabies treatment in the UK, and is only available through specialist importers. Standard treatment consists of topical acaracides, applied over the whole body same day to all residents and staff, left on usually overnight before showering, and repeated seven days later. This is labour intensive and can be distressing, especially for residents with dementia who may not understand why it is happening.\(^2\) Unsurprisingly crusted scabies cases (often present in these outbreaks) can be resistant to topical treatment due to the barrier of hyperkeratotic skin crusts. This vulnerable population, often at the end of life, deserves better.

Unfortunately, ill-founded safety concerns about ivermectin use in the elderly still deter clinician use, arising from a 1997 letter\(^3\) published in The Lancet. The authors reported increased mortality in a group of 47 long-term health facility residents (the majority with dementia) treated with oral ivermectin for scabies compared to retrospective, inadequately matched controls. Potential confounding was acknowledged but the authors still advised against ivermectin use in the elderly. The letter was criticised at the time for methodological errors, and data presented from other outbreaks did not demonstrate an association between ivermectin and mortality.\(^4\) Mass Drug Administrations have since been conducted across the
world. Recent modelling work re-analysed the letter’s data, showing it did not conclusively demonstrate ivermectin caused excess mortality. Yet despite all this, twenty-two years after the letter was published, elderly people in the UK experiencing distressing outbreaks of a Neglected Tropical Disease are still deprived access to an effective treatment that’s relative ease of administration would allow greater dignity in care.

In line with WHO we call for steps to enable access to this essential medicine, and we recommend its wider use for scabies by UK clinicians. We also urge The Lancet to place an editorial warning on the 1997 letter, pointing to the WHO endorsed status of ivermectin treatment for ectoparasitic infections, and stating the report was flawed.